Pathology: es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1);
es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | ||
GeparQuinto, 2012 | SYSUCC-002, 2022 | ||
trastuzumab plus endocrine therapy | 1 | T1 | |
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | |
trastuzumab plus chemotherapy | 0 | T0 | |
lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 |